NCT07212322 (ET-902-AID01) is a NA clinical trial of CD19 UCAR-T cells in Systemic Lupus Erythematosus, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT07212322?

NCT07212322 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT07212322?

Interventions in NCT07212322: CD19 UCAR-T cells.

What condition does NCT07212322 study?

NCT07212322 studies Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome, Antiphospholipid Syndrome, Immune Thrombocytopenia, Systemic Sclerosis.

Is NCT07212322 still recruiting?

NCT07212322 is currently not yet recruiting. Last updated 19 December 2025.

Last reviewed 2025-12-19 · How we verify

NCT07212322: ET-902-AID01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases

Not yet recruiting NA Last updated 19 December 2025

What this trial tests

NA trial testing CD19 UCAR-T cells in Systemic Lupus Erythematosus in 24 participants. Not yet recruiting.

Timeline

30 January 2026

Primary endpoint
20 May 2027

20 July 2027

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	30 January 2026
Primary completion	20 May 2027
Estimated completion	20 July 2027
Sites	1 location across China

Drugs / interventions tested

CD19 UCAR-T cells — full drug profile →

Conditions studied

Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →
Idiopahic Inflammatory Myopathies — all drugs for Idiopahic Inflammatory Myopathies →
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis — all drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis →
Sjögren's Syndrome — all drugs for Sjögren's Syndrome →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 65, any sex, with Systemic Lupus Erythematosus or Idiopahic Inflammatory Myopathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Systemic Lupus Erythematosus

Currently open trials in the same condition.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) · Phase 1 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07212322 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 19 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07212322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing